Replacing antibodies with aptamers in lateral flow immunoassay

Chen, Ailiang; Yang, Shi‐Yao

doi:10.1016/j.bios.2015.04.041

Cited by 463 publications

(238 citation statements)

References 125 publications

Supporting

Mentioning

228

Contrasting

Unclassified

Order By: Relevance

“…29 Aptamers have the advantages of being highly specific, relatively small in size, and easily synthesized, which could be regarded as a chemical equivalent of antibodies. 30,31 In this study, we adopted a truncated aptamer A10-3.2 with 39 nucleotides for its simplicity of chemical synthesis and enhanced specificity. It is about 55% of the full A10 in size.…”

Section: Discussionmentioning

confidence: 99%

A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growthin vivo

Yanjun

Liu

et al. 2016

Cancer Biology & Therapy

View full text Add to dashboard Cite

Specific and efficient delivery of siRNA into intended tumor cells remains as a challenge, even though RNAi has been exploited as a new strategy for prostate cancer therapy. This work aims to address both specificity and efficiency of SURVIVIN-siRNA delivery by constructing a therapeutic complex using combinatorial strategies. A fusion protein STD was first expressed to serve as a backbone, consisting of streptavidin, a cell-penetrating peptide called Trans-Activator of Transcription (TAT) and a doublestranded RNA binding domain. A biotinylated Prostate Specific Membrane Antigen (PSMA) specific aptamer A10 and SURVIVIN-siRNA were then linked to STD protein to form the therapeutic complex. This complex could specifically targeted PSMA C tumor cells. Compared to lipofectamine and A10-siRNA chimera, it demonstrated higher efficiency in delivering siRNA into target cells by 19.2% and 59.9%, and increased apoptosis by 16.8% and 26.1% respectively. Upon systemic administration, this complex also showed significant efficacy in suppressing tumor growth in athymic mice (p <0.001). We conclude that this therapeutic complex could specifically and efficiently deliver SURVIVIN-siRNA to target cells and suppressed tumor growth in vivo, which indicates its potential to be used as a new strategy in prostate cancer therapy

show abstract

Section: Discussionmentioning

confidence: 99%

A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growthin vivo

Yanjun

Liu

et al. 2016

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Aptamers have been used as 'antibody mimics' or alternatives to antibodies in some chromatographic binding assays [17][18][19][20]. These binding agents consist of single-stranded DNA or RNA sequences that are often 10 to 100 nucleotides in length and that have the ability to form highly ordered 3D structures [19].…”

Section: Antibodies and Related Binding Agentsmentioning

confidence: 99%

“…These binding agents consist of single-stranded DNA or RNA sequences that are often 10 to 100 nucleotides in length and that have the ability to form highly ordered 3D structures [19]. Aptamers are prepared through a selection and amplification process known as SELEX (i.e., the 'systematic evolution of ligands by exponential enrichment'), which can be used to generate specific binding agents with relatively high affinities for a particular target [17,18].…”

Section: Antibodies and Related Binding Agentsmentioning

confidence: 99%

“…Aptamers are prepared through a selection and amplification process known as SELEX (i.e., the 'systematic evolution of ligands by exponential enrichment'), which can be used to generate specific binding agents with relatively high affinities for a particular target [17,18]. These agents have been used to bind targets that have included drugs, peptides, proteins and cells [17][18][19][20]. It is possible to easily modify the structure of an aptamer to include a label or to immobilize the aptamer to a support [18,19].…”

Section: Antibodies and Related Binding Agentsmentioning

confidence: 99%

“…These agents have been used to bind targets that have included drugs, peptides, proteins and cells [17][18][19][20]. It is possible to easily modify the structure of an aptamer to include a label or to immobilize the aptamer to a support [18,19]. In addition to being used in biosensors [17,18], aptamers have been employed in chromatography for both the purification of proteins [20] and in various forms of chromatographic binding assays [19].…”

Section: Antibodies and Related Binding Agentsmentioning

confidence: 99%

See 2 more Smart Citations